RPA Joint Coenzyme Q10(Coenzyme Q10) In The Treatment Of Acute St Segment Elevation Myocardial Infarction Recent Clinical Cliniczl Curative Effect

Objective:through this experiment observed in patients with acute ST segment elevation myocardial infarction acute phase used in the treatment of rPA thrombolysis therapy and rPA thrombolysis treatment of STEMI combined use of coenzyme Q10 intravenous drip injection at the same time, the grouping to observe the curative effect of two groups of patients and drugs after the application of security. Methods:through the patient’s symptoms and electrocardiogram examination related to diagnosis for STEMI meet emergency thrombolytic therapy against 80 patients were randomly divided into conventional thrombolysis treatment group and the combined use of coenzyme Q10 intravenous drip treatment group, each group of 40 patients, thrombolysis treatment group for the use of thrombolytic therapy alone, coenzyme Q10 group on the basis of thrombolytic therapy for coenzyme Q10 intravenous drip therapy at the same time. Respectively before and after treatment by thrombolysis in patients after 24 hours monitoring of the patient’s serum troponin I (cTnI), creatine kinase isoenzyme (CK-MB), superoxide dismutase (SOD); And evaluation in 2 weeks after treatment with the group of patients with heart colour to exceed check, Simpson method is used to measure and calculate the left ventricular end-diastolic diameter, left ventricular end systolic diameter and left ventricular ejection fraction; And through the above treatment in different observation 2 groups of patients after treatment within 2 weeks after collection value, of cardiovascular adverse events in patients with calculating the ratio. Results 1, combined coenzyme Q10 treatment group is higher than the rate of blood vessel thrombolysis treatment group (65.7%,62.8%), no two groups through statistical analysis is a statistical significance (P> 0.05).2, the two groups after treatment monitoring CK-MB, cTnI, SOD before treatment were significantly increased, and the SOD rise significantly lower than that of CK-MB, the rise of cTnI amplitude (P< 0.05), after the combined therapy with coenzyme Q10 monitoring CK-MB, cTnI rise less than thrombolytic drug treatment group, the activity of SOD were higher than thrombolytic drug treatment group, data processing and statistical analysis are statistically significant (P< 0.05).3, conventional intravenous thrombolysis treatment group monitoring heart colour to exceed after 2 weeks left ventricular end-diastolic diameter, left ventricular end systolic diameter joint coenzyme Q10 values are higher than the treatment group, left ventricular ejection fraction below joint coenzyme Q10 treatment group (56.01 50.69+/-2.99 mm +/-3.48 mm, P< 0.05; 47.89 41.88+/-4.67 mm+/-4.76 mm, P< 0.05,53.84+/-4.92 than 60.29+/-6.74, P< 0.05), the value via statistical analysis are statistically significant.4, joint coenzyme Q10 treatment group compared with thrombolysis treatment group adverse events occurred in acute myocardial infarction (ami) such as angina pectoris, myocardial infarction, again after malignant arrhythmia decreased significantly (P< 0.05), after statistics treatment there is statistical significance; The incidence of cardiac shock, death, and bleeding in the two groups by statistical analysis of no statistical significance (P> 0.05). Conclusion: in the protection of patients with acute myocardial infarction (mi) in myocardial reperfusion injury combined use of coenzyme Q10 more effective than single use rPA, at the same time, combined use of coenzyme Q10 intravenous drip for reducing coronary artery recanalization after recent cardiac adverse events obviously reduce the complications are compared, than original kinase epoetin organised fibrinolytic enzyme derivatives (rPA) thrombolysis therapy has more advantages.